Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 13, 2026

Phenol Red Thread-based Sampling Procedure for Untargeted Tear Fluid Lipidomics in Biomarker Discovery
08:16

Phenol Red Thread-based Sampling Procedure for Untargeted Tear Fluid Lipidomics in Biomarker Discovery

Published on: December 12, 2025

Tirofiban for Reduction of TEAR: A Phase 2, Randomized, Open-Label, Blinded End Point, Controlled Trial.

Xinyan Hu1,2,3, Qianmei Jiang1,2,3, Ning Wang4

  • 1Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, China. (X.H., Q.J., A.W., Z.Z., J.C., Y.W., X.X., J.J.).

Stroke
|June 12, 2026
PubMed

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictive Value of Composite Inflammatory Markers for Stroke Prognosis: A Prospective Cohort Study.

Annals of clinical and translational neurology·2026
Same author

Magnetic resonance-guided laser interstitial thermal therapy for mesial temporal lobe epilepsy (MINE): a single-centre, prospective, randomised, open-label, blinded-endpoint controlled trial protocol in China.

BMJ open·2026
Same author

Early Cardiac Workload and Long-Term Prognosis After Intracerebral Hemorrhage: Insights from a Large Multicenter Cohort.

Reviews in cardiovascular medicine·2026
Same author

Unexpected widespread amyloid PET positivity in a patient with CADASIL.

Journal of neurology·2026
Same author

Early and severe masticatory muscle involvement in SOD1-ALS: a case report with biomarker-clinical dissociation.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same author

Dual Antiplatelet Therapy and Immediate Intensive Statin in Mild Ischemic Stroke: A Randomized Trial.

Neurology·2026
Summary

Prophylactic tirofiban significantly reduced new infarct lesions after treating unruptured intracranial aneurysms. This neurointerventional therapy showed no increase in bleeding or mortality, warranting further study.

Area of Science:

  • Neurointerventional radiology
  • Vascular neurology
  • Pharmacology

Background:

  • Thromboembolism is a frequent complication following interventional treatment of unruptured intracranial aneurysms.
  • Glycoprotein IIb/IIIa inhibitor tirofiban presents a potential strategy to mitigate these thromboembolic events during neurointerventional procedures.

Purpose of the Study:

  • To evaluate the efficacy and safety of prophylactic tirofiban in patients undergoing neurointerventional therapy for unruptured intracranial aneurysms.

Main Methods:

  • A phase 2, prospective, randomized, open-label, blinded end-point trial (TEAR) enrolled 191 adult patients with unruptured intracranial aneurysms.
  • Patients received either intravenous tirofiban with dual antiplatelet therapy or dual antiplatelet therapy alone during endovascular aneurysm repair.
Keywords:
glycoproteinintracranial aneurysmmagnetic resonance imagingthromboembolismtirofiban

Related Experiment Videos

Last Updated: Jun 13, 2026

Phenol Red Thread-based Sampling Procedure for Untargeted Tear Fluid Lipidomics in Biomarker Discovery
08:16

Phenol Red Thread-based Sampling Procedure for Untargeted Tear Fluid Lipidomics in Biomarker Discovery

Published on: December 12, 2025

  • Primary outcome: number and volume of new ischemic lesions on diffusion-weighted imaging within 48 hours postprocedure.

    • Main Results:

    • Adjunctive tirofiban significantly reduced the median volume of new infarcts (48.6 vs 88.2 mm³, P=0.007) and showed a trend towards fewer new infarction lesions (P=0.046).
    • No significant differences were observed in symptomatic stroke, intracranial hemorrhage, or major bleeding rates between groups at 48 hours or 30 days.

    Conclusions:

    • Prophylactic intravenous tirofiban, when combined with dual antiplatelet therapy, effectively reduces new postoperative infarct lesions.
    • The treatment was found to be safe, with no increase in hemorrhagic complications or mortality.
    • Further validation in large-scale, multicenter trials is recommended.